August 23, 2007 - GE Healthcare announced that it has received U.S. Food and Drug Administration (FDA) approval for its new mobile mammography product, Senographe Essential, designed to improve access to breast cancer screening.
As medical organizations continue to offer full-field digital mammography in a mobile setting, GE Healthcare's newest mobile unit will reportedly feature the largest digital detector in the mammography market, advanced ergonomic design for the technologist, optimized patient comfort and seamless workflow connectivity. The foundation of the Senographe Essential Imaging is GE's advanced digital detector, which is said to deliver the industry's highest Detective Quantum Efficiency (DQE), the standard for quantifying digital X-ray image quality at low doses.
For more information: www.gehealthcare.com
July 29, 2024 
